Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Metrics to compare | TECX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTECXPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.6x | −3.4x | −0.5x | |
PEG Ratio | −0.07 | 0.01 | 0.00 | |
Price/Book | 1.3x | 2.6x | 2.6x | |
Price / LTM Sales | - | 9.3x | 3.3x | |
Upside (Analyst Target) | 266.6% | 197.5% | 45.4% | |
Fair Value Upside | Unlock | 15.1% | 7.7% | Unlock |